Quality Begins Before the Vesicle Exists

PEXT is designed around a principle that is frequently overlooked in the extracellular-vesicle market: the quality of a regenerative product begins with the biological fitness and consistency of the cells that produce it. Culture conditions, cellular state, source material, isolation methods, and storage can all influence extracellular-vesicle yield, composition, and function.

PEXT therefore moves quality control upstream—before conditioned media are collected, before vesicles are isolated, and before the final product is stabilized. The objective is not simply to produce more particles, but to build a more measurable and reproducible biological platform.

What Are Extracellular Vesicles and Exosomes?

Extracellular vesicles, or EVs, are lipid-bilayer particles naturally released by cells. They carry combinations of proteins, lipids, metabolites, and nucleic acids that can participate in communication between cells.

Exosomes are a specific subtype of EV formed through the endosomal pathway within the producing cell. Because the precise intracellular origin of every isolated vesicle cannot always be demonstrated in a finished preparation, the MISEV2023 scientific guidelines recommend using broader terms such as “extracellular vesicles” or “small extracellular vesicles” unless exosomal biogenesis has been specifically established. This distinction is not a weakness; it is a sign of scientific precision.

The Source Matters—but Source Alone Is Not Enough
Human regenerative EV platforms most commonly use mesenchymal stromal cells derived from bone marrow, adipose tissue, umbilical cord, or Wharton’s jelly. Other platforms use platelets, induced pluripotent stem cell-derived cells, immune cells, or engineered producer cells. Each source may generate a different molecular profile, and comparative proteomic studies have demonstrated source-dependent differences in cargo and biological activity. However, no source is universally superior for every application. Donor condition, cellular age, population heterogeneity, passage number, culture environment, isolation method, and quality controls may be just as important as the name of the source tissue itself.

Platelet-derived EVs reflect the natural signaling environment associated with clotting and wound response, and early human research has explored their potential in delayed wound healing. Plant-derived vesicle-like nanoparticles offer abundance and manufacturing scalability, but they represent a biologically different and less clinically mature category than human MSC-derived EVs. Engineered and recombinant platforms can provide greater molecular definition and scalability, although they do not reproduce the full complexity of a native cellular secretome.

Source Is a Starting Point, Not a Quality Certificate

Two cell populations originating from the same tissue can differ substantially in redox status, stress resistance, biological consistency, and secretory behavior. PEXT is designed to evaluate the cells themselves rather than assuming that tissue origin automatically guarantees quality.

The PEXT source-cell assessment platform examines four complementary glutathione-related parameters:
Glutathione Mean Level (GM) reflects the central intracellular glutathione level of the cell population.
Glutathione Heterogeneity (GH) reflects the degree of biological variability within that population.
Glutathione Regeneration Capacity (GRC) evaluates the ability of cells to restore their glutathione balance following an oxidative challenge.

Oxidative Stress Resistant Capacity (ORC) identifies the proportion of cells capable of maintaining high glutathione levels under oxidative stress. Together, these parameters create a multidimensional assessment of source-cell fitness. Rather than selecting cells by origin alone, PEXT uses measurable biological characteristics to identify populations with the desired quality profile before production begins.

Clean, Controlled Cell Culture

Following source-cell selection, PEXT production is designed around phenol red-free and animal component-free culture conditions. Eliminating unnecessary culture components helps reduce avoidable process variables and supports clearer control over the environment in which extracellular vesicles and conditioned media are generated. This should not be described simply as “organic production.” It is more accurately defined as a controlled, clean, and biologically focused manufacturing strategy.

The quality of an EV preparation cannot be separated from the environment in which its producer cells were maintained. For this reason, culture conditions are treated as part of the product—not merely as a preliminary laboratory step.

What Are Exosomes Used for Today?

In the current commercial market, EV- and exosome-associated products are most commonly encountered as topical cosmetic or professional aesthetic formulations intended to support the appearance and condition of the skin or scalp. Separately, clinical-stage biotechnology companies are investigating EV-based products as potential medicinal products. These two categories must not be presented as if they have the same regulatory status or level of evidence.

In the United States, the FDA states that exosome products intended to treat diseases or medical conditions require regulatory approval and that there are currently no FDA-approved exosome products for such therapeutic use. Commercial cosmetic positioning must therefore remain clearly separated from investigational medical research.

Responsible Commercialization in an Evolving Regulatory Landscape

PEXT is currently presented as a Regenerative Powder within the cosmetic framework applicable to its authorized intended topical use. It is not presented as an approved drug, injectable treatment, or product intended to diagnose, treat, cure, or prevent disease.
Product classification is determined by intended use, claims, composition, route of administration, presentation, and the requirements of each jurisdiction. In the European Union, borderline classification decisions are made case by case, while cosmetic claims must meet standards of legal compliance, truthfulness, evidential support, honesty, fairness, and informed decision-making. The responsible strategy is therefore not to call the law “unclear,” but to distinguish clearly between what is commercially available today and what remains under scientific or clinical investigation.

Why Fibronectin Matters

Fibronectin is a high-molecular-weight extracellular-matrix glycoprotein involved in cell adhesion, migration, tissue organization, and interactions with integrin receptors. Scientific studies have shown that fibronectin can also be associated with the surface of extracellular vesicles in certain biological systems. In those systems, EV-associated fibronectin can contribute to integrin-dependent binding, cellular uptake, and functional cargo delivery.
Fibronectin is therefore not a substitute for an extracellular vesicle, nor does its presence mean that a preparation is “not an exosome.” It can be a meaningful functional component within EV biology. At the same time, fibronectin is not a universal exosome marker, and fibronectin alone cannot establish the identity, purity, concentration, or biological activity of an EV preparation. Those characteristics require multi-parameter analytical evidence.
This distinction explains the PEXT labeling strategy: the INCI-facing ingredient identity and the wider biological description of the platform answer two different questions. INCI nomenclature provides a standardized ingredient name for cosmetic labeling; comprehensive characterization explains the biological nature and quality of the preparation. An ingredient’s appearance in the European Commission’s CosIng database does not, by itself, constitute product authorization or proof of regulatory approval.

Why PEXT Is Different

PEXT does not aim to differentiate itself by repeating the word “exosome” more loudly or by presenting particle count as the entire definition of quality. It is designed to connect five levels of evidence:
Source-cell quality: measurable glutathione status, homogeneity, regenerative capacity, and oxidative-stress resistance.
Production environment: controlled, phenol red-free and animal component-free culture conditions.
Product characterization: identity, particle profile, purity, molecular composition, and relevant biological activity.
Stabilization: a validated lyophilization and reconstitution process.
Batch transparency: defined acceptance criteria and traceable lot-release information.
The importance of PEXT lies in this upstream-to-downstream quality architecture. It transforms quality from a marketing adjective into a sequence of measurable decisions.

Two Celleva Platforms. Two Different Scientific Purposes.

The PEXT Native Biologics Platform is designed to preserve the biological complexity of selected producer cells. It generates EV-rich conditioned media and purified extracellular-vesicle preparations from source-cell populations chosen according to defined glutathione and homogeneity parameters. This platform is appropriate when the coordinated, multi-molecular signaling environment of native cell biology is desired.
The PEXT NEW Recombinant Precision Platform is being developed for applications in which molecular definition, production consistency, scalability, and a human-cell-free process are the primary priorities. Using recombinant DNA technology, a defined human Fibronectin gene sequence is introduced into a controlled microbial expression system to produce sequence-defined recombinant human Fibronectin without the use of human producer cells.
These technologies are not competitors. Native biologics provide complex biological communication, while recombinant manufacturing provides a more defined molecular product. Celleva selects the platform according to the intended purpose, desired biological profile, manufacturing requirements, and applicable regulatory pathway.
Two Pathways. One Standard.
Celleva combines source-cell intelligence, native biologics, recombinant precision technology, and evidence-led manufacturing to provide the most appropriate regenerative platform for each scientific, commercial, and regulatory objective.
Not every application requires the same product. Every application requires the same commitment to measurable quality.
The research information presented on this website is educational and describes the wider scientific field. It does not establish PEXT as an approved medical treatment and should not be interpreted as medical advice.
A new quality-defined exosome platform built on measurable source-cell glutathione parameters and population homogeneity

THE CELLEVA DUAL-PLATFORM STRATEGY:

ENGINEERED FOR TRUST, TAILORED FOR NEED

At Celleva, our commitment to "Innovating Healing" requires us to be at the absolute pinnacle of biotechnology—a position that demands both mastery of natural processes and advanced genetic engineering. The regenerative medicine landscape is complex, with varying legal regulations, specific patient objectives, and distinct market demands. A "one-size-fits-all" approach cannot deliver excellence in every scenario.

Therefore, Celleva has developed two separate, state-of-the-art production platforms, operating in full compliance with cGMP and cGLP standards. We don't just innovate; we customize.

Our PEXT (Native/Organic) platform is for those who demand the finest natural-origin products. We select source cells based on strict, objectively validated criteria, including high glutathione levels and maximum homogeneity, to produce the world’s most potent, pure, and animal-free exosomes and conditioning media (CM).

Simultaneously, our PEXT New (Engineered/Recombinant) platform solves the challenges of global regulatory restrictions and ethical concerns related to human-tissue derivatives. Using advanced rDNA technology, we transfer decoded human gene sequences, like Fibronectin, into a pristine microbial host. This groundbreaking process synthesizes 100% bio-identical, ultra-pure proteins—without using a single human cell.

By operating these two distinct platforms, Celleva ensures we can provide the ideal, most suitable regenerative solution, precisely tailored to meet specific purpose requirements and comply with any regional legal frameworks, always without compromising quality or safety.

Beyond Exosomes: The Core of Regeneration

For years, the aesthetic industry has relied on traditional exosomes and stem cell secretomes. However, biological variability, low purity, and regulatory constraints have limited their true potential.

Until now.

Welcome to PEXT—a paradigm shift in regenerative medicine. We didn't just extract exosomes; we decoded them. By identifying Fibronectin as the ultimate master-molecule of the stem cell secretome responsible for tissue repair, we isolated its genetic sequence and recreated it with 100% purity.

The Result: The biological intelligence of an exosome, delivered with the pharmaceutical precision of a recombinant protein. Zero human tissue. Zero legal gray areas. Infinite regenerative potential.

The Mastery of Bio-Engineering: Recombinant DNA Technology

PEXT is not harvested; it is meticulously engineered. Our breakthrough lies in our proprietary Recombinant DNA (rDNA) Technology, ensuring a product that is bio-identical to human tissue but synthesized with absolute purity.

How We Build the Future of Tissue Repair:

• Genetic Sequencing: We isolate the precise human gene sequence responsible for Fibronectin—the critical "scaffold" protein found in the most potent stem cell secretomes.
• Plasmid Integration: This bio-identical sequence is safely introduced into a high-yield microbial host (Escherichia coli).
• Precision Fermentation: In state-of-the-art bioreactors, the host synthesizes pure, high-molecular-weight Fibronectin that perfectly mimics human extracellular matrix (ECM) properties.
• Ultra-Purification: The protein is extracted and rigorously purified, resulting in a 100% cell-free, pathogen-free, and ethically sound active ingredient.

Powered by Freshtracer™ Technology Quality you can see, trace, and trust. Every batch of PEXT is validated by Freshtracer™ technology, ensuring molecular stability, optimal protein folding, and objective proof of efficacy from the lab to your clinic. The Ultimate Formulation: Fibronectin + Glutathione

PEXT introduces a dual-action mechanism that transforms the cellular environment.

1. Recombinant Fibronectin (The Builder):

• Acts as the ultimate molecular bridge, enabling optimal cell adhesion and migration.
• Mimics the "hand-shaking" mechanism of exosomes, directly signaling fibroblasts to synthesize new collagen and elastin.
• Rebuilds the Extracellular Matrix (ECM) from the ground up.

2. Premium Glutathione (The Protector):

• The master antioxidant.
• Neutralizes free radicals instantly, protecting the newly formed cellular scaffold from oxidative stress.
• Promotes a luminous, even skin tone by inhibiting melanin synthesis at the cellular level.

Together, they create an impenetrable regenerative shield. Fibronectin lays the foundation, and Glutathione protects the masterpiece.

PEXT

Precision. Purity. Performance.

Why Choose PEXT Over Traditional Exosomes?

• 100% INCI Compliant: Fully registered cosmetic ingredient. No regulatory risks.
• Absolute Consistency: Standardized protein concentration in every single vial.
• Ethical & Safe: Cruelty-free, pathogen-free, and completely human-cell free.
• Unmatched Efficacy: Clinically engineered for rapid downtime reduction and deep tissue rejuvenation.

Elevate Your Practice. Designed exclusively for advanced aesthetic professionals.

FREQUENTLY ASKED QUESTIONS

Clarity & Compliance: Everything You Need to Know

1. Is PEXT legally compliant and safe to use in my clinic? Absolutely. Unlike human-derived exosomes and secretomes, which currently face strict regulatory bans and restrictions globally (including EU regulations), PEXT is a 100% cell-free, bio-engineered product. It is fully compliant with cosmetic and aesthetic regulatory frameworks. You can integrate PEXT into your practice with absolute legal peace of mind.

2. Does PEXT contain human DNA, human cells, or human tissue? Zero. This is the core of our biotechnology. While the Recombinant Fibronectin in PEXT is synthesized using a decoded human gene sequence, the actual production takes place in a sterile, cell-free microbial host environment. There are no human cells, no donor tissues, and absolutely no risk of human pathogen transmission. It is ethically sound and scientifically pure.

3. Why should I choose PEXT over traditional exosome therapies? Because in regenerative medicine, what matters is not the amounts of particles but the function. Traditional exosomes are highly heterogeneous; their quality and safety fluctuate wildly from donor to donor. PEXT isolates the ultimate functional core—Fibronectin and Glutathione—delivering standardized, objectively proven potency in every single vial. No guesswork, just pure engineered healing.

4. Can I combine PEXT with Energy-Based Devices (EBDs) and microneedling? Yes, it is engineered specifically for this synergy. PEXT acts as the ultimate post-procedure scaffold and shield. When applied after lasers, RF, or microneedling, the Glutathione instantly neutralizes thermal and oxidative stress, dramatically reducing downtime and erythema. Simultaneously, the Recombinant Fibronectin initiates immediate structural rebuilding in the dermis.

5. What is the overarching philosophy behind the PEXT formulation? Our philosophy is simple: Youth decoded, beauty coded. We decoded the fundamental requirements of cellular repair and coded them into a perfect, repeatable, and flawless biotechnology. PEXT doesn't just treat the skin; it reprograms the extracellular matrix to its most optimal state.